University of Groningen
Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases
Ghalandari, N; Dolhain, R J E M; Hazes, J M W; van Puijenbroek, E P; Kapur, M; Crijns, H J
M J
Published in: DRUGS
DOI:
10.1007/s40265-020-01376-y
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date: 2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Ghalandari, N., Dolhain, R. J. E. M., Hazes, J. M. W., van Puijenbroek, E. P., Kapur, M., & Crijns, H. J. M. J. (2020). Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review. DRUGS, 80(16), 1699-1722. https://doi.org/10.1007/s40265-020-01376-y
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Vol.:(0123456789)
https://doi.org/10.1007/s40265-020-01376-y
SYSTEMATIC REVIEW
Intrauterine Exposure to Biologics in Inflammatory Autoimmune
Diseases: A Systematic Review
N. Ghalandari1,2,4 · R. J. E. M. Dolhain1,4 · J. M. W. Hazes1,2,4 · E. P. van Puijenbroek3 · M. Kapur5 · H. J. M. J. Crijns2 Published online: 27 August 2020
© The Author(s) 2020
Abstract
Background Inflammatory autoimmune diseases are chronic diseases that often affect women of childbearing age. Therefore, detailed knowledge of the safety profile of medications used for management of inflammatory autoimmune diseases during pregnancy is important. However, in many cases the potential harmful effects of medications (especially biologics) during pregnancy (and lactation) on mother and child have not been fully identified.
Objective Our aim was to update the data on the occurrence of miscarriages and (major) congenital malformations when using biologics during pregnancy based on newly published articles. Additionally, we selected several different secondary outcomes that may be of interest for clinicians, especially information on adverse events in the use of a specific biologic during pregnancy.
Material and Methods A search was conducted from 1 January 2015 until 4 July 2019 in Embase.com, Medline Ovid, Web of Science, Cochrane CENTRAL, and Google Scholar with specific search terms for each database. Selection of publications was based on title/abstract and followed by full text (double blinded, two researchers). An overview was made based on out-comes of interest. References of the included publications were reviewed to include and minimize the missing publications.
Results A total of 143 publications were included. The total number of cases ranged from nine for canakinumab to 4276 for infliximab. The rates of miscarriages and major congenital malformations did not show relevant differences from those rates in the general population.
Conclusion Despite limitations to our study, no major safety issues were reported and no trend could be identified in the reported malformations.
Key Points
The rates of miscarriages and major congenital malfor-mations after exposure to biologics during pregnancy do not deviate from these rates in the general population. It is likely that use of adalimumab, certolizumab pegol, and etanercept is safe during pregnancy.
Data on risks of using abatacept, anakinra, canakinumab, golimumab, rituximab, tocilizumab, ustekinumab, and vedolizumab are scarce.
Electronic supplementary material The online version of this article (https ://doi.org/10.1007/s4026 5-020-01376 -y) contains supplementary material, which is available to authorized users. * N. Ghalandari
n.ghalandari@erasmusmc.nl
1 Department of Rheumatology, Erasmus University Medical
Center, Rotterdam, The Netherlands
2 Medicines Evaluation Board (MEB), Graadt van Roggenweg
500, 3531 AH Utrecht, The Netherlands
3 Netherlands Pharmacovigilance Centre Lareb,
‘s Hertogenbosch, The Netherlands
4 Academic Center of Inflammunity, Erasmus University
Medical Center, Rotterdam, The Netherlands
5 Utrecht University of Medical Sciences, Utrecht,
1 Introduction
Chronic inflammatory diseases such as rheumatoid arthri-tis (RA), psoriatic arthriarthri-tis (PsA), ankylosing spondyliarthri-tis (AS), inflammatory bowel disease (IBD), and psoriasis, are common in women of childbearing age [1–3].
Active disease may not only be harmful for the mother, but also carries a risk for the fetus. There is an overlap between biologics used for the management of rheumatic, gastroenteric, and dermatologic autoimmune diseases. Even though biologics have shown efficacy in keeping the dis-ease under control, their safety profile in pregnant women is still uncertain. Based on the mode of action, biologics are classified into tumor necrosis factor (TNF)-α inhibi-tors and non-TNF biologics. At present, pregnancy registry data have become available for only four TNF-α inhibitors (adalimumab, certolizumab pegol, etanercept, and inflixi-mab) [4–7]. For other biologics (non-TNF-α inhibitors) and biosimilars used during pregnancy in autoimmune diseases there is still insufficient information on the occurrence of adverse events such as congenital malformations (CMs). As a precaution, the use of such medications during pregnancy is discouraged before acquisition of reassuring results from a pregnancy registry. In addition, unintentional exposure to medication(s) may also occur in cases of unplanned preg-nancies. Accordingly, knowledge on the safety of medication during pregnancy is of great importance [8–10].
In the pre-authorization period, pregnant women are excluded from randomized clinical trials (RCTs) for ethi-cal reasons. After authorization, the main available data are collected prospectively by different registries or ret-rospectively from healthcare databases, and in some cir-cumstances published as case reports. Summarizing the available data in a systematic review can be helpful to gain a better perspective on the use of different biologics during pregnancy and lactation.
The European League Against Rheumatism (EULAR) have published a systematic review on this topic (search period 2008–2015) [8]. However, it is important to provide up-to-date knowledge based on published data after this period. In this regard, a meta-analysis that included data from 24 studies was published by Tsao et al., in which the authors pooled the available evidence to assess the impact of biologic therapy during pregnancy [11]. This current sys-tematic review aimed to update the data on the impact of maternal exposure to biological therapy by focusing specifi-cally on miscarriages and (major) CMs. Furthermore, in this systematic review, each biologic is considered separately and the pattern of reported CMs is documented. Other clinically
relevant outcomes such as vaccination response, detectable drug levels during different stages of pregnancy, infections, and stillbirths are also investigated.
Thus the aim of this systematic review was to update the data on miscarriages and (major) CMs separately for each biologic used in inflammatory autoimmune diseases, based on newly published articles since 2015. Due to overlap in indications of biologics between rheumatic diseases, IBD, and psoriasis, studies on the use of biologics in IBD and psoriasis were also included.
2 Materials and Methods
A PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) [11] guideline was followed in the design of this study.
2.1 Protocol and Registration
This systematic review was registered retrospectively at PROSPERO under the code CRD42019135316. The recorded protocol was not provided prospectively in PROS-PERO [12].
2.2 Information Sources and Search Strategy A systematic search was conducted in the following data-bases: Embase.com, Medline Ovid, Web of Science, Cochrane CENTRAL, and Google Scholar. The search strat-egy was designed and conducted by an experienced librar-ian with input from the study’s main investigator (NG). The Medical Subject Heading (MeSH) terms used for each data-base are detailed in the Electronic Supplementary Material (ESM). The search only included articles published from 1 January 2015 until 4 July 2019.
2.3 Study Selection and Data Collection Process All relevant citations were saved in a bibliographic reference manager (Endnote × 9 version, Thomson Reuters, Philadel-phia, PA, USA) and duplicates were removed. Titles and abstracts were analyzed according to inclusion and exclu-sion criteria (see Box 1). Additional citations were identified from the reference list of all previously selected articles. The selection process was conducted by two researchers (NG and IC) with a medical background, by reviewing the titles and the abstracts, independently. Discrepancies were resolved through discussions at consensus meetings.
2.4 Data Items, Outcomes, and Prioritization Primary outcomes were defined as:
1. Miscarriages Spontaneous loss of pregnancy before 24 weeks of gestation, also known as spontaneous abor-tion [13];
2. Major CMs Conditions caused by failure of a particular body site or body system to develop correctly during the antenatal period, which had medical implications, required surgical repair, or were life threatening. (The list of malformations considered as major can be found in Supplementary Table 1) [14].
Other variables for which data were sought were catego-rized in two groups:
1. Maternal-related outcomes:
(a) Ectopic pregnancies Any condition character-ized by implantation of the embryo outside the endometrium and endometrial cavity during preg-nancy;
(b) Induced abortions The removal of an embryo or fetus from the uterus at a stage of pregnancy when it is deemed incapable of independent survival; at any time between conception and the 24th week of gestation (GW);
(c) Pregnancy-related hypertension Gestational hypertension, pre-eclampsia, and eclampsia; (d) Premature rupture of membranes Spontaneous
rupture of fetal membranes before the onset of labor;
(e) Emergent caesarian sections Unplanned caesarian section (C-section) due to maternal/fetal condi-tion; other types/uncategorized C-sections were not considered in the results;
Box 1. Inclusion and exclusion criteria
Following publica ons were included:
- Cohort studies, case-control studies, case reports, registry studies, pharmacological signaling studies and abstracts (RCTs are not included in this study, as all the inves gated biologics are registered before 01/01/2015)
- Full text in English, German, Dutch, French, Spanish or any other languages, provided that an English abstract was available
- Publica ons published a er 01/01/2015
Following publica ons were excluded:
- Duplicate ar cles
- Meta-analysis, literature review ar cles, editorial ar cles, animal/in-vitro studies, comments, research le ers - Ar cles without an English abstract
- Studies on diseases other than rheumatoid, gastroenterological and dermatologic autoimmune diseases - Ar cles that do not provide informa on about the outcome of the pregnancies exposed to biologics
- Studies with same popula on source as another included ar cle (the most recent ar cle was chosen to be included in these situa ons)
- Only Paternal exposure
(f) Flare-up during pregnancy/post-partum Active disease during pregnancy/during 6 months after delivery;
(g) Detectable drug concentration in breast milk 2. Child-related outcomes:
(a) Minor CMs Conditions caused by failure of a par-ticular body site or body system to develop cor-rectly during the antenatal period, which pose no significant health problem in the neonatal period and tend to have limited social or cosmetic conse-quences for the affected individual, were consid-ered minor CMs;
(b) Live births The complete expulsion or extrac-tion from the mother of a baby, irrespective of the duration of the pregnancy, which, after such separation, breathes or shows any other evidence of life;
(c) Still birth A baby born with no signs of life at or after 24 weeks of gestation;
(d) Neonatal death Death during the first 28 days of life;
(e) Low birth weight When the infant was born weigh-ing less than 2500 g;
(f) Pre-term birth When the infant was born before 37 weeks of gestation;
(g) Small for gestation age (SGA) When birth weight was below − 2 standard deviations of the mean or below the 10th percentile according to local intrauterine growth charts;
(h) Adequate vaccination response Measured by labo-ratory findings on immune response after vaccina-tion;
(i) Adverse drug reactions (ADRs) related to vaccinations; (j) Allergies;
(k) Eczema;
(l) Serious/opportunistic infections Infections that required medical intervention/hospitali-zation;
(m) Anti-drug antibodies at birth in the newborn; (n) Detectable drug levels
(i) in cord blood
(ii) in infant’s blood at birth
(iii) during first 6, 9, and 12 months of life;
(o) Abnormal development Physical/psychologi-cal developmental delay in children.
ther variables for which data were sought were categorized in two groups.
Data that did not meet mentioned definitions were not considered in the final results.
2.5 Risk of Bias in Individual Studies
The quality of the studies was scored by awarding points in each domain following the guidelines of the New-castle–Ottawa Scale (NOS) for either cohort studies or case–control studies. The NOS assigns up to a maximum of nine points for the least risk of bias in three domains: (1) selection of study groups (four points); (2) comparability of groups (two points); and (3) exposure or outcome (three points) for case–control and cohort studies (see Supplemen-tary Table 2, ESM) [15].
2.5.1 Summary Measures
Numbers of cases occurred for each specific outcome and with exposure to each specific biologic were extracted from each article and entered into the chart.
2.5.2 Risk of Bias Across Studies
Due to heterogeneity of the data the calculated percentages are up to clinical interpretations and comparison of the out-comes should be performed with caution.
2.5.3 Data Synthesis
All included articles were considered in data synthesis if they had reported at least one outcome for a specific bio-logic. Percentage of occurrence for each outcome was calculated as cumulative number of cases divided by the
population, for which that specific outcome was reported in the included publications.
2.5.4 Confidence in Cumulative Evidence
The cumulative evidence of the studies was assessed by GRADE scoring (The Grading of Recommendations Assessment, Development and Evaluation Working Group; [retrieved 17 September 2019]) and the score of the Oxford Centre for Evidence-Based Medicine (CEBM) [retrieved 17 September 2019] [16–18].
The GRADE approach results in an assessment of the quality of evidence on four levels: (1) high (++++), (2) moderate (+++), (3) low (++), and (4) very low (+) based on all publications and their limitations. First a primary ranking of ‘high’ or ‘low’ was assigned to RCTs or obser-vational studies (if included for the specific group of pub-lications for one specific biologic). Then the initial ranking was downgraded or upgraded based on among others risk of bias, inconsistency, imprecision, indirectness, confounding in cumulative evidence based on all included publications for the specific biologic. It should be mentioned that the final score is not an average of individual scores, but a cumulative assessment for all the publications together, as explained above [16, 18].
The strength of cumulative evidence was graded using a 1–5 ordinal scale for CEBM, in which the lower the risk of confounding (bias), the further to the left the type of evi-dence will lie in the scale. Steps were taken as for GRADE score and final score was assigned to the cumulative evi-dence from all publications included for one biologic at a time [17].
For both the GRADE scoring and the CEBM calcula-tions the included studies and case reports were weighted considering case–control studies are recommended studies for identifying congenital anomalies [19] followed by cohort studies and case reports, as they have the lowest weight. Abstracts scored lower than full articles, because the meth-ods section often does not sufficiently describe the control group and the adjusting for confounders. The GRADE and CEBM scores based on these considerations are presented in Table 1.
3 Results
3.1 Study Selection
A total of 4823 articles were primarily extracted from the mentioned databases up to 4 July 2019. Selection of pub-lications was based on title/abstract and followed by full text (double blinded, two researchers). 151 articles were excluded after reading the full text based on the following
reasons: duplicate articles (including abstracts/posters that had published full texts) (n = 69), information on the out-come of the pregnancies exposed to biologics not provided (n = 64), studies with the same population source as another included article (n = 13), in vitro studies (n = 3), only pater-nal exposure was investigated (n = 1), studies on diseases other than intended for this article (n = 1). References of the included articles were screened for additional inclusion. Nine additional articles were added to the dataset sheets based on reference-screening of included articles. A total of 143 articles were included. The steps taken are shown in Fig. 1.
3.2 Study Characteristics
In total 143 publications were included. The number of pub-lications for each biologic ranged from two (canakinumab) to 59 (infliximab). The references, type of publications, and GRADE and Oxford CEBM scores for each biologic are presented in Table 1.
3.3 Risk of Bias Within the Studies
The authors acknowledge the risk of information bias in some studies that evaluated pooled data on several biolog-ics, without reporting the numbers of outcomes for each bio-logic separately. The results of these studies, however, are described in this article as two additional categories under the subtitles of “TNF alpha blocker (in general, not specified in the full text)”and “Biologics (in general, not specified in the full text)”.
3.4 Results of Individual Studies and Synthesis of the Results
The key outcomes for each biologic are discussed below. To gain a better perspective regarding overall possible confounders, data on maternal characteristics such as dis-ease type, co-morbidities, concomitant medication expo-sure, presence of anti-drug antibodies in maternal serum, exposure during the first and all three trimesters, and rate of breastfeeding after delivery were calculated, if possible (Table 2). Outcome measures are presented in Tables 3 and 4 for maternal- and child-related outcomes, respectively. It
noi ta cifi tn edI gni ne erc S ytili bigi lE de dul cnI
Publications identified through literature database searches N = 4823
Publications after duplicate removal and screening based on title/abstract
N = 285
Excluded publications based on
inclusion/exclusion criteria after reading title/abstract, N= 4538
Excluded publications based on
inclusion/exclusion criteria after reading the full text, N= 151
Publications after screening based on full text N =134
Publications with data on sought outcomes N= 143
Additional articles based on reference-screening from included atricles, N = 9
should be noted that due to heterogeneity of the data the calculated percentages cannot be compared.
3.4.1 Abatacept
In total 157 maternal pregnancies were investigated in five articles. Outcomes regarding miscarriages were investigated for 153 of these pregnancies, in which 40 miscarriages were reported (26.1%).
Seven major CMs were reported in 88 pregnancies (7.9%), which included:
1. Cleft palate (n = 1)
2. Congenital aortic-anomaly (n = 1) 3. Meningocele (n = 1)
4. Pyloric stenosis (n = 1)
5. Skull malformation (unspecified) (n = 1) 6. Ventricular septal defect (VSD) (n = 1) 7. Congenital arterial malformation (n = 1) [9].
The percentage and variety of co-medication use (includ-ing methotrexate (MTX) exposure) could not be extracted for the reported miscarriages from the presented data.
3.4.2 Adalimumab
A total of 2027 maternal pregnancies were described in 50 articles. Outcomes regarding miscarriages were reported for 180 pregnancies, in which 16 miscarriages occurred (8.9%). Forty-six (n = 46) major CMs were reported in 1008 preg-nancies (4.6%). Thirteen major CMs were described as fol-lows (the other cases did not describe explicitly the major CM or the major CM could not be linked to this specific biologic):
1. Cleft palate (n = 1).
2. Cleft palate, micrognathia, myopia, glaucoma and esophageal motility disorder (n = 1).
3. Congenital diaphragmatic hernia and obstructive mega ureter (n = 1).
4. Polydactyly (n = 1). 5. Hexadactyly (n = 1).
6. Hexadactyly both feet and atrial septal defect (ASD) (n = 1).
7. Esophageal atresia with tracheo-esophageal fistula, VSD, syndactyly in both feet, peripheral pulmonary stenosis, persistent foramen ovale (PFO) (n = 1).
Table 1 Summary of the references and GRADE scores (confidence in cumulative evidence)
Drug Number and type of publications References GRADE CEBM
Abatacept 1 cohort, 2 register data (2 abstracts), 2 case
reports/series (1 abstracts) [9, 20–23] ++ 3–4
Adalimumab 19 cohorts (9 abstract), 14 register data (6 abstract), 6 case controls (1 abstract), 11 case reports/series (3 abstract)
[1, 20–69] +++ 3
Anakinra 4 cohorts (1 abstract), 2 case reports/series [20, 57, 70–73] + 4
Canakinumab 1 cohort, 1 case report (1 abstract) [72, 74] + 4
Certolizumab pegol 14 cohorts (6 abstract), 10 register data (1 abstract), 4 case controls (1 abstract), 4 case reports/series (3 abstract)
[1, 20, 22, 23, 31, 33, 37, 39, 40, 42, 44, 48, 54,
55, 57, 58, 63, 64, 66, 68, 75–88] ++ 3–4
Etanercept 12 cohorts (5 abstract), 6 register data (2 abstract), 2 case controls (1 abstract), 6 case reports/series (2 abstract)
[1, 20–23, 27, 33, 35, 40, 41, 44, 45, 47, 53–57,
60, 63, 66, 68, 87, 89–91] +++ 3
Golimumab 9 cohorts (2 abstract), 3 register data (1 abstract), 2 case controls (1 abstract), 2 case reports/series (1 abstract)
[20, 22, 23, 33, 35, 40, 44, 48, 53–55, 58, 64, 66,
68, 80] + 4
Infliximab 23 cohorts (11 abstract), 13 register data (2 abstract), 3 case controls, 20 case reports/series (10 abstract)
[1, 20–25, 28, 31, 34–38, 40, 42–44, 46–48, 51,
53, 55, 57, 58, 60–62, 64–68, 76, 77, 79, 80,
92–112]
++ 3–4
Rituximab 5 cohorts (2 abstract), 3 register data (2 abstract), 1
case reports/series (1 abstract) [20, 22, 44, 45, 56, 57, 63, 66, 113] + 4 Tocilizumab 1 cohort, 1 register data (1 abstract), 8 case
reports/series (3 abstract) [22, 23, 41, 45, 114–119] ++ 3–4
Ustekinumab 4 cohorts, 3 register data (2 abstract), 15 case
reports/series (3 abstract) [27120, 37–130, 44], 53, 59, 60, 64, 66, 67, 77, 80, + 4 Vedolizumab 2 cohorts (1 abstract), 1 register data, 2 case
controls (1 abstract), 2 case reports/series (1 abstract)
Table 2 Mater nal c har acter istics of pr egnancies e xposed t o differ ent biologic dr ugs Dr ug Abat acep t Adali -mumab Anakinr a Canaki -numab Cer tolizumab pegol Et aner cep t Golimumab Infliximab Rituximab Tocilizumab Us tekinumab Vedolizumab Indications Rheumat oid diseases 4/157 (2.5) 118/2,027 (5.8) 7/35 (20) 9/9 (100)* 318/883 (36) 458/1145 (40) 9/31 (29) 34/4276 (0.8) 42/42 (100) 340/373 (91.2) 1/54 (1.9) – Inflammat or y bo wel disease – 1182/2027 (58.3) – – 328/883 (37.2) – 5/31 (16.1) 2539/4276 (59.4) – – 23/54 (42.6) 147/147 (100) Psor iasis – 12/2027 (0.6) 3/35 (8.6) – – 97/1145 (8.5) – 10/4276 (0.2) – – 26/54 (48.1) – N ot defined/ other 153/157 (97.4) 715/2027 (35.2) 25/35 (71.4) – 237/883 (26.8) 591/1145 (51.6) 17/31 (54.8) 1693/4276 (39.6) – 33/373 (8.8) 5/54 (9.3) – Pr e-pr egnancy e xis ting co-morbidities APS 0/1 (0) 0/19 (0) 0/1 (0) – 1/12 (8.3) 0/74 (0) 0/4 (0) 0/20 (0) 0/2 (0) – – – Diabe tes 5/151 (3.3) – – – – 36/337 (10.7) – – – – – – Hospit aliza -tion/sur ger y – 1/5 (20) – – – – – 34/260 (13.1) – –-– 1/5 (20) Hyper tension † – – 1/5 (20) – – 74/337 (22) – 2/16 (12.5) – 1/16 (6.2) – – Ment al disor -ders – – – – – 126/337 (37.4) – 0/14 (0) – 1/16 (6.2) – – Smok er – 8/63 (12.7) 1/5 (20) – 0/6 (0) – – 53/333 (15.9) – 1/14 (7.1) – – Alcohol – – 1/5 (20) – – – – 0/16 (0) – 0/14 (0) – – Pr evious mis -car riag es – 0/4 (0) 1/4 (25) 1/8 (12.5) – – –-3/19 (15.8) – 33/304 (10.9) – – Pr evious unf er -tility – 5/58 (8.6) 1/5 (20) – – – – 3/73 (4.1) – – – – P er ianal com -plications – 12/58 (20.6) – – 2/27 (7.4) – – 3/115 (26.1) – – – 6/39 (15.4) Th yr oid dis -function – – – – – 38/337 (11.3) – 0/14 (0) – 1/16 (6.2) – – Ot her – – – – – – – – – 1/16 (6.2) + – 1/20 (5) ++ Concomit ant exposur e (an y) – 71/278 (25.5) 4/5 (80) – 402/553 (72.7) 70/353 (19.8) – 85/461 (42.9) 5/23 (21.7) 54/210 (25.7) – 6/34 (17.6) Cor ticos ter oid – 11/61 (18.1) – – 14/30 (46.7) – – 90/450 (20) 15/27 (55.6) 0/2 (0) 3/35 (8.6) Cy clospor ine – – – – 0/4 (0) 0/5 (0) – 2/228 (0.9) 2/23 (8.7) – 1/2 (50) –
Table 2 (continued) Dr ug Abat acep t Adali -mumab Anakinr a Canaki -numab Cer tolizumab pegol Et aner cep t Golimumab Infliximab Rituximab Tocilizumab Us tekinumab Vedolizumab Hydr oxy chlo -roq uine – – – – 6/21 (28.6) – – – 3/22 (13.6) 1/16 (6.2) – – Leflunomide – 1/9 (11.1) – – 0/6 (0) 0/31 (0) – – 4/23 (17.4) 2/17 (11.7) – – Mesalazine – 5/58 (8.6) – – 0/3 (0) – – 124/348 (35.6) – – – 4/9 (44.4) MTX – 6/80 (7.5) 0/5 (0) – 0/25 (0) 59/343 (17.2) – 36/221 (16.3) 5/23 (21.7) 40/208 (25.6) – 0/10 (0) NS AID – – 1/5 (20) – 5/13 (38.5) – – – – – – – Sulf asalazine – – – – 5/21 (23.8) – – – 5/22 (22.7) 1/16 (6.2) – 1/24 (4.2) Thiopur ines – 33/136 (24.3) – – – – – 116/296 (39.2) 2/22 (9.1) – – 2/10 (20) An
y non- biologic DMARDs
– – – – – 23/337 (6.9) – 5/57 (8.8) – – – – Ano ther bio -logic – 23/803 (2.9) – 2/8 (25) 3/17 (17.6) 23/337 (6.8) – 21/819 (2.6) 2/22 (9.1) 1/4 (25) – Ot her – – 1/4 (25) Col -chicine – 394/541 (72.8) Any dr ugs 46/337 (13.6) Tera to -genic DMARDs – 63/83 (75.9) Folic acid – – – – Anti-dr ug anti -bodies – 2/16 (12.5) – – 0/21 (0) – – 0/2 (0) – – – – Exposur e per iod F irs t tr imes ter – 529/534 (99) 29/34 (85.3) 9/9 (100) 424/528 (80.3) 252/268 (94) 10/10 (100) 510/675 (75.6) 9/25 (36) 341/355 (96.1) 22/25 (88) 38/47 (80.8) All t hr ee trimes ters 0/2 (0) 19/78 (24.3) 25/33 (75.8) 4/9 (44.4) 9/41 (21.9) 19/256 (7.4) 0/10 (0) 20/94 (21.3) 3/25 (12) 10/355 (2.8) 12/31 (38.7) 35/47 (74.4) Br eas tfeeding – 19/78 (24.3) 14/25 (56) – 9/41 (21.9) 5/27 (18.5) – 20/94 (21.3) – 5/39 (12.8) 1/4 (25) 12/75 (16) Values ar e giv en as number (%) NS AID non-s ter oidal anti-inflammat or y dr ugs, MTX me tho tre xate, HCQ h ydr oxy chlor oq uine, ADRs adv erse dr ug r eactions, RA rheumat oid ar thr itis, JIA juv enile r heumat oid ar thr itis, AS anky -losing spondy litis, PsA psor iatic ar thr itis, FMF familial Mediter ranean f ev er , APS anti-phospholipid syndr ome, DMARDs disease-modifying antir heumatic dr ugs † Not r elated t o pr egnancy *4/9 C APS (cr yop yr in-associated per iodic f ev er syndr omes), 1/9 Cog an syndr ome, and 1/9 no t defined + Pr evious pr egnancy com plications ++ Obesity
8. ASD with left–right shunt and aneurysm, cavum sep-tum pellucidum on both sides, hemangioma at left flank (n = 1).
9. VSD and hip dysplasia (n = 1).
10. Hemangioma right temple, umbilical hernia (n = 1). 11. Imperforate anus (n = 1).
12. Amniotic band sequence: talipes and amputation of four fingers of the right hand (n = 1).
13. Cystic adenomatoid malformation of the right lung, incomplete right bundle branch block, pericardial effusion, PFO, persistent ductus arteriosus (PDA) and slight persistent pulmonary hypertension (co-medica-tion: etanercept) (n = 1) [1, 20, 68].
Data on overall concomitant medication was available for 278 cases. Use of one or more co-medications was reported for 71 of these patients (25.5%). Data on exposure to MTX were available for 80 cases, of which six patients (7.5%) were exposed to MTX.
Growth was investigated in 61 children exposed to adali-mumab during pregnancy, of which only one primary growth failure due to cystic fibrosis was reported (1.6%) [43].
Adalimumab was detectable in breast milk of two patients from the total 21 investigated cases (9.5%), with a maxi-mum concentration of 0.71 μg/mL seen between 12 and 24 h after injection. In seven cases breast milk was examined after 7 days from the injection and it was not detectable in any of these cases [80].
3.4.3 Anakinra
In total 35 maternal pregnancies were investigated in six articles. Outcomes regarding miscarriages were investigated for 33 of these pregnancies, in which only one miscarriage was reported (3.1%, concomitant therapy was not reported in this case) [72]. One major CM was reported (2.9%, unilat-eral renal agenesis and ectopic neurohypophysis, which also had abnormal growth due to growth hormone deficiency) [72]. One minor CM (a case of tied tongue after exposure to anakinra during pregnancy [73]) was reported among nine cases that were investigated for such an outcome. Data on overall concomitant medication was available for five cases. Use of one or more co-medications was reported for four of these patients (80.0%). MTX exposure was not reported for any of these patients.
Emergent C-sections were reported in two cases. One case because of a pathological cardiotocography (CTG) and premature rupture of the membranes and umbilical cord entanglement. The other case was a secondary emer-gent C-section due to uterine rupture under spontaneous delivery [70].
3.4.4 Canakinumab
In total nine pregnancies were investigated in two articles [72, 74]. Outcomes regarding miscarriages were investigated for all of these pregnancies, in which only one miscarriage was reported (11.1%, at 6 weeks of pregnancy to a mother with refractory Cogan syndrome). Concomitant medication was not reported in this case [72]. No CMs were reported in eight live births. Data on overall concomitant medication (including MTX exposure) were not available.
3.4.5 Certolizumab Pegol
In total 883 maternal pregnancies were investigated in 32 articles. Outcomes regarding miscarriages were investigated for 679 of these pregnancies, in which 78 miscarriages were reported (11.5%). Ten major CMs were reported from a total of 535 investigated cases (1.9%). In the article by Broms et al. the described major CMs were not categorized based on the kind of biologic used during pregnancy. Therefore, the one reported case of major CM for certolizumab pegol in this study could not be associated with the described cases [40]. Nine described cases in other articles could be linked to certolizumab pegol and were as follows (the rest of the cases were not described explicitly or could not be linked to this specific biologic):
1. Clubfeet and Hirschsprung’s disease (n = 1) 2. Anal fistula (n = 1)
3. Talipes (n = 1)
4. Vesicoureteric reflux (n = 1) 5. Cerebral ventricle dilatation (n = 1) 6. Hydronephrosis (n = 1)
7. Congenital heart disease (n = 1) 8. Accessory auricle (n = 1) 9. Polydactyly (n = 1) [75, 78].
Data on overall concomitant medication were avail-able for 553 cases. Use of one or more co-medications was reported for 402 of these patients (72.7%). Data on exposure to MTX were available for 25 cases, of which none were exposed to MTX.
From the two reported cases of early membrane ruptures, one was due to infection [75]. The other one occurred at the 35th week in a mother exposed to certolizumab pegol during the first trimester [1].
Reported infections in mothers were mainly urinary tract infections and upper respiratory tract infections. In one case pyelonephritis with septicemia at 30th GW was reported in a patient who was on certolizumab pegol combination therapy with hydroxychloroquine, sulfasalazine, and pred-nisone [75].
Table 3 Outcomes of pr egnancy e xposur e r elated t o differ ent biologic dr ugs Dr ug Abat acep t Adalimumab Anakinr a Canaki -numab Cer tolizumab pegol Et aner cep t Golimumab Infliximab Rituximab Tocilizumab Us tekinumab Vedolizumab Number of pr egnancies 157 2027 35 9 883 1145 31 4276 42 368 54 147 Pr ospectiv e 99 (63.1) 898 (44.3) 8 (22.9) 1 (11.1) 641 (72.6) 657 (57.4) 15 (48.4) 2453 (57.4) 35 (83.3) 204 (55.4) 36 (66.7) 58 (39.5) Re trospectiv e 58 (36.9) 1129 (55.7) 27 (77.1) 8 (88.9) 242 (27.4) 488 (42.6) 16 (51.6) 1823 (42.6) 7 (16.7) 164 (44.6) 18 (33.3) 89 (60.5) Pr egnancy r elated outcomes Misscar riag es (to tal) 40/153 (26.1) 16/180 (8.9) 1/33 (3.1) 1/9 (11.1) 78/679 (11.5) 69/359 (19.2) – 170/1584 (10.7) 1/24 (4.2) 84/361 (23.3) 3/27 (11.1) 19/72 (26.4) Pr ospectiv e 17/70 (24.3) 11/121 (9.1) 1/27 (3.70) 0/1 (0) 47/556 (8.5) 0/4 (0) – 169/1551 (10.9) 1/19 (5.3) 43/199 (21.6) 1/17 (5.9) 9/57 (15.8) R etr ospectiv e 23/83 (27.7) € 5/59 (8.4) 0/6 (0) 1/8 (12.5) 31/123 (25.2) 69/355 (19.4) – 1/33 (3) 0/5 (0) 41/162 (25.3) 2/10 (20) 10/15 (66.7) Ect opic pr eg -nancy – – 0/6 (0) – 0/3 (0) – – 9/1363 (0.7) – 0/16 (0) – – Induced abor -tion 20/153 (13.1) 3/86 (3.5) 0/5 (0) – 37/679 (5.4) 30/338 (8.9) – 90/1552 (5.8) 1/19 (5.3) 6/69 (8.7) 1/26 (3.8) 7/57 (12.3) Diseases dur ing pr egnancy Placent al abnor malities – 0/6 (0) – – 1/23 (4.3) – – 1/6 (16.7) – – – 2/4 (50) Pr egnancy -related hyper tension – 1/5 (20) – – 5/454 (1.1) 74/362 (20.4) – – 1/19 (5.3) 1/20 (5) – 1/21 (4.8) Ges tational diabe tes 5/148 (3.4) 1/53 (1.8) – – 6/468 (1.3) – – – – – – – Ser ious inf ec -tions – 1/6 (16.6) 1/9 (11.1) – 25/543 (4.6) 33/363 (9.1) – 2/8 (25) – – – – Ot her – – – – – 40/337 (11.9) ∞ – – – – – – Deliv er y Ear ly mem -br ane r up tur e 1/86 (1.2) 0/5 (0) 1/5 (20) – 2/17 (11.8) 1/25 (4) – 1/7 (14.3) – 53/288 (18.4) – – Emer gent C-section 1/86 (1.2) 0/4 (0) 2/4 (50) – 1/16 (6.2) – – 6/1372 (0.4) – 2/5 (40) – 2/33 (6.1)
Table 3 (continued) Dr ug Abat acep t Adalimumab Anakinr a Canaki -numab Cer tolizumab pegol Et aner cep t Golimumab Infliximab Rituximab Tocilizumab Us tekinumab Vedolizumab Dose r ang e (N ) † – 40 mg/2w (14), 40 mg/w (6) 50 mgD (2), 100 mgD (21), 200– 300 mgD (1) 120 mg once (1), 150 mg/8w (4), 300 mg/8w (1), 150 mg/4w (2) 200 mg/2w (36), 400 mg/4w (3) – – 5 mg/k g/8w (37) ††, 5 mg/ kg/6w (14), 7.5 mg/ kg/8w (1), 5 mg/ kg/4w (8), 10 mg/ kg/8w (2), 10 mg/ kg/6w (4), 10 mg/ kg/4w (1) – 4 mg/k g/4w (13), 8 mg/ kg/4w (147) 45 mg/12w (5), 90 mg/12w (3), 90 mg/8w (1), 45 mg/2w (1), 90 mg/4w (1) 300 mg/8w (13) De tect able in br eas t milk – 2/21 (9.5) – – 13/25 (52) – 0/1 (0) 19/29 (65.5) – 4/4 (100) 4/6 (66.7) 5/5 (100) Values ar e giv en as number (%) W w eek , D dail y † Dat a on dose w er e no t r etr act able in all t he cases, t he number of patients, f or whom dose w as r epor ted, is mentioned in br ac ke t ins tead of per cent ag es. Doses ar e mentioned fr om lo wes t t o t he highes t in or der †† In tw o cases infliximab w as used at dose of 5 mg/k g one t o t hr ee times dur ing t he t hir d tr imes ter , t he r es t of t he cases w er e adminis ter ed dur ing all t he tr imes ters € The r es t of t he pr ospectiv e and r etr ospectiv e dat a w er e no t dis tinguished ∞ Hemor rhag e
Table 4 Child-r elated outcomes of pr egnancy e xposur e r elated t o differ ent biologic dr ugs Dr ug Abat acep t Adalimumab Anakinr a Canaki -numab Cer toli -zumab pegol Et aner cep t Goli -mumab Infliximab Rituximab Tocilizumab Us teki -numab Vedoli -zumab Bir th-r elated outcomes Liv e bir th 88/152 (57.8) 200/222 (90.0) 32/33 (96.9) 8/9 (88.9) 582/702 (82.9) 270/372 (72.6) 6/6 (100) 1740/2017 (86.3) 19/24 (79.2) 218/362 (60.2) 26/30 (86.7) 39/69 (56.5) Ma jor CMs (t ot al) 7/88 (7.9) 46/1008 (4.6) 1/34 (2.9) 0/8 (0) 10/535 (1.9) 47/815 (5.8) 0/13 (0) 51/1222 (4.2) 0/20 (0) 11/345 (3.2) 0/28 (0) 2/110 (1.8) Pr ospectiv e 0/36 (0.0) 25/543 (4.6) 1/27 (3.7) 0/1 (0) 10/507 (2) 30/466 (6.4) 0/8 (0) 28/751 (3.7) 0/20 (0) 8/194 (4.1) 0/18 (0) 2/40 (5) R etr ospectiv e 7/52 (13.4) € 21/465 (4.5) 0/7 (0) 0/7 (0) 0/28 (0) 17/349 (4.9) 0/5 (0) 23/471 (4.9) – 3/151 (2) 0/10 (0) 0/70 (0) Minor CMs – 2/68 (2.9) 1/9 (11.1) – – 0/20 (0) 0/2 (0) 2/94 (2.1) – 0/4 (0) 0/19 (0) 1/5 (20) Lo w bir th w eight (< 2500 g) 0/1 (0) 11/123 (8.9) 6/19 (31.6) 0/6 (0) 25/243 (10.3) 31/253 (12.2) 0/2 (0) 65/584 (11.1) 0/6 (0) 27/118 (22.9) 2/24 (8.3) 1/9 (11.1) Pr e-ter m bir ths (< 37 w eek s) – 4/146 (2.7) 6/28 (21.4) 0/8 (0) 42/380 (11.1) 40/269 (14.9) 0/2 (0) 104/1,754 (5.9) 0/19 (0) 32/177 (18.1) 3/20 (15) 16/94 (17) SG A – 1/87 (1.1) – – 5/463 (1.1) 0/48 (0) 0/5 (0) 3/106 (2.8) 0/6 (0) 3/39 (7.7) – – S till bir th/intr au -ter ine deat h (≥ 20 w eek s) 4/151 (2.6) 2/258 (0.8) 0/32 (0) – 5/570 (0.9) 0/30 (0) – 2/2,146 (0.1) 2/30 (6.7) 1/202 (0.5) 0/23 (0) 1/28 (3.6) N eonat al deat h – – 0/32 (0) – 2/543 (0.4) 0/29 (0) – 0/435 (0) 0/30 (0) 0/3 (0) 0/14 (0) – Immune sy stem-r elated outcomes A deq uate v acci -nation r esponse – 17/17 (100) – – 9/9 (100) 25/26 (96.2) 2/2 (100) 12/12 (100) – – 1/1 (100) – ADRs r elated t o vaccination – 1/102 (0.9) – – 0/26 (0) 0/12 δ (0) – 6/197 (3) – – 0/3 (0) 0/1 (0) Aller gies – 5/103 (4.9) – – – – – 8/183 (4.4) – – – – Eczema – 6/44 (13.6) – – – – – 15/61 (24.6) – – – – (Ser ious/oppor tun -istic) inf ections Ψ 0/17 (0) 13/229 (5.7) 0/30 (0) 0/8 (0) 2/41 (4.9) 0/62 (0) 0/4 (0) 212/786 (27) 0/13 (0) 0/3 (0) 0/7 (0) 5/110 (4.6) Dr ug-r elated outcomes Anti-dr ug anti -bodies at bir th – – – – 0/16 (0) – – 4/51 (7.8) – – – – De tect able dr ug le vels Cor d blood – 50/50 (100) – – 6/26 (23.1) – – – – – – – A t bir th – 28/36 (77.8) – – 1/14 (7.1) – – 51/99 (51.5) – – – – Dur ing firs t 6 mont hs – – – – 0/14 (0) – – – – – – 0/5 (0)
Two cases of neonatal deaths occurred in a twin preg-nancy; one of the twins was born at 25th GW with brain damage and pneumo-peritoneum, the other twin was born at 27th GW with heart defects and passed away due to a gastrointestinal infection at the 8th week of age [78].
Concentration in breast milk was investigated in 13 cases. Certolizumab pegol was detectable in three of these cases with a maximum concentration of 0.29 μg/mL peak. In two cases breast milk was examined after 7 days following the injection, and it was not detectable in either case [80].
3.4.6 Etanercept
In total 1145 maternal pregnancies were investigated in 26 articles. Outcomes regarding miscarriages were investigated for 359 of these pregnancies, in which 69 miscarriages were reported (19.2%). From 815 exposed cases during preg-nancy, 47 major CMs were reported (5.8%). Six described cases are as follows (the rest of the cases were not described explicitly or could not be linked to this specific biologic): 1. Hypoplastic left heart and hypospadias (n = 1) 2. Agenesis of left kidney (n = 1)
3. Bilateral hydronephrosis (n = 1) 4. ASD (n = 1)
5. Wolf–Parkinson–White syndrome with heart failure (n = 1)
6. Omphalocele (n = 1) [55, 68].
Data on overall concomitant medication were avail-able for 353 cases. Use of one or more co-medications was reported for 70 of these patients (19.8%). Data on exposure to MTX were available for 343 cases, in which 59 patients (17.2%) were exposed to MTX.
3.4.7 Golimumab
In total 31 maternal pregnancies were investigated in 16 pub-lications. No data regarding miscarriages could be extracted from the presented information in these articles. No major CMs were reported in 13 exposures during pregnancy for golimumab. Data on overall concomitant therapy (including MTX exposure) were not available.
3.4.8 Infliximab
In total 4276 maternal pregnancies were investigated in 59 articles. The largest amount of prospective data was reported from a Janssen biologics database, which reported preg-nancy results of 1362 reported spontaneous cases, clinical studies, and registries [101]. Outcomes regarding miscar-riages were investigated for 1584 of these pregnancies, in which 170 miscarriages were reported (10.7%).
Table 4 (continued) Dr ug Abat acep t Adalimumab Anakinr a Canaki -numab Cer toli -zumab pegol Et aner cep t Goli -mumab Infliximab Rituximab Tocilizumab Us teki -numab Vedoli -zumab A t 9 mont hs of age – 1/37 (27) – – – – –-7/46 (15.2) – – – – A t 12 mont hs of age – 0/36 (0) – – – – – 3/46 (6.5) – – – – A bnor mal de vel -opment – 1/61 (1.6) 1/32 (3.1) 0/8 (0) 0/8 (0) – – 33/533 (6.2) – 0/3 (0) 0/4 (0) 0/5 (0) Values ar e giv en as number (%) SGA (small f or g es tational ag e): belo w 10t h centile f or w eight at bir th, CM cong enit al malf or mation. Ψ Ser ious inf
ections defined as antibio
tic t her ap y or hospit alization because of t he inf ection
δ Vaccinations including polio, hepatitis B, dipht
her
ia, per
tussis, te
tanus, Haemophilus influenza, and pneumococcus v
accines at 3, 6, and 12 mont
In total 51 major CMs were reported in 1222 pregnancies (4.2%). Fourteen described major CMs are as follows (the rest of the cases were not described explicitly or could not be linked to this specific biologic):
1–3. VSD (n = 3). 4, 5. Cleft palate (n = 2). 6, 7. Facial hemangiomata (n = 2). 8. ASD (n = 1) 9. Ectrodactyly (n = 1) 10. Polydactyly (n = 1)
11. Hydronephrosis and obstructive megaureter (n = 1) 12. Pelviureteric junction obstruction (n = 1)
13. Small aortic-pulmonary collateral, hypospadias, hepatic cyst (n = 1)
14. Megacystis plus bilateral talipes (n = 1) [43, 68, 107– 109].
Two cases of minor CMs were reported in 94 patients (2.1%). This included one case of duplex kidney and one case of aberrant subclavian artery [136]. Data on overall concomitant medication were available for 461 cases. Use of one or more co-medications was reported for 85 of these patients (42.9%). Data on exposure to MTX were available for 221 cases, of which 36 patients (16.3%) were exposed to MTX.
Five hundred and forty-seven patients from a total of 1939 (28.2%) were exposed to infliximab during the entire pregnancy (all three trimesters). The data on elimination of infliximab during pregnancy were available only from a pharmacokinetics (PK) study, which compared drug levels and its clearance during different trimesters in 22 pregnan-cies. It was reported in this study that infliximab clearance decreased by 12% in the second and third trimesters [112].
The median ratio of infliximab in cord blood to maternal level was 2.63 (95% confidence interval (CI), 1.67–4.03) in 52 patients [median duration of therapy until 23 GW (range 21–32)] [43] and 3.25 in two patients in another study (therapy continued until last week of gesta-tion) [28]. In one case report in a patient under infliximab treatment with the dose of 10 mg/kg every 6 weeks until the 32th GW, the cord blood concentration was 110.1 μg/ mL. Plasma infliximab level in the mother at the time of delivery was 59.7 µg/mL [93]. The median ratio of infant to maternal drug concentration at birth was 1.97 (95% CI 1.50–2.43) in 44 patients (18 patients and 26 patients received last infusion before and after the 30th GW, respectively) [136]. In another study the median con-centration was 7.8 μg/mL in patients who used infliximab until the 18th–36th weeks of gestation [51].
Infliximab was detectable in 19 patients’ breast milk out of a total of 29 patients, with a maximum range of 0.15–0.74 μg/mL 24 h after infusion, detectable in 17
samples from a total of 29 after 48 h, and detectable in five samples from a total of eight after 168 h (no concentrations were reported for samples in the last two groups). Weight-adjusted dose was not calculated in this study [80].
Six cases from a total of 1372 (0.4%) required emergency C-section. One of these cases had undergone an emergency C-section because of placental dysfunction, in which a very low-birth-weight preterm infant was born [99].
There was a case report of an infant diagnosed with vertical transmission of disseminated histoplasmosis from mother at the time of delivery and through the placenta (authors’ conclusion: probable involvement of the central nervous system). The mother was taking infliximab (IBD indication) until the 32th GW (delivery at 35th GW) [93].
A follow-up of 533 children exposed to infliximab showed abnormal development in 33 of these children (6.2%). Descriptions of abnormal development were provided in three of these cases: two cases reported deviations in weight or height percentiles and one case of late gross motor func-tion development, which was resolved by 20 months of age [43, 94, 109].
Regarding vaccination (one or more vaccinations with Bacillus Calmette-Guérin (BCG), rotavirus, Haemophilus influenzae type b (Hib), tetanus, or hepatitis B), in total 197 cases were investigated in different publications [1, 43, 51, 58, 62, 77, 94, 100, 109, 137]. Twenty-nine cases were investigated regarding response to tetanus and hepatitis B vaccination, of which 28 had adequate response [28, 51, 62, 77, 100]. Adverse drug reactions were reported in six cases with mild reactions to rotavirus vaccination (fever, n = 5 and diarrhea, n = 1) in children exposed to infliximab during pregnancy [77].
3.4.9 Rituximab
In total 42 maternal pregnancies were investigated in nine articles. Outcomes regarding miscarriages were investi-gated for 24 of these pregnancies, of which only one (4.2%) miscarriage was reported at 12th GW in a case exposed to rituximab 1 month prior to conception and MTX at the time of conception [113].
No major CMs were reported for 20 pregnancy cases expose to rituximab. Data on exposure to MTX were avail-able for 23 cases. It was reported for five of these patients (21.7%).
Two cases of stillbirth were reported, which occurred in the same patient, with rituximab exposure at 9 and 18 months prior to conception [113].
3.4.9.1 Tocilizumab In total 368 maternal pregnancies were investigated in ten articles. Outcomes regarding mis-carriages were investigated for 361 of these pregnancies, in which 84 miscarriages were reported (23.3%). Data on
con-comitant exposure to MTX for reported miscarriages were not available.
Eleven major CMs were reported in a total of 345 inves-tigated pregnancies with tocilizumab (3.2%). Eight of these cases were described as follows:
1. Pyelectasia (n = 1)
2. Multicystic dysplasia of right kidney (n = 1) 3. Esophageal fistula (n = 1)
4. Coarctation of the aorta, VSD, and inguinal hernia (n = 1)
5. Absence of one cardiac cavity (n = 1) 6. Bilateral hip dysplasia (n = 1) 7. Polydactyly (n = 1)
8. Marked thoracic scoliosis, myelomeningocele, missing sacrum (caudal regression syndrome) (n = 1) [117]. Data on overall concomitant medication were avail-able for 210 cases. Use of one or more co-medications was reported for 54 of these patients (25.7%). Data on exposure to MTX were available for 203 cases, in which 40 patients (19.7%) were exposed to MTX. The results of these pregnan-cies were reported for just two cases (both live births, in one of them tocilizumab, MTX, and hydroxychloroquine till the sixth week of gestation). One case of stillbirth occurred in a pregnancy also exposed to MTX.
Concentration in breast milk was investigated in one study, in which drug concentrations of between 6 and 60,000 ng/mL were measured up to 28 days after admin-istration of 400 mg tocilizumab, with a peak concentration before day 7. The time taken to reach the maximum con-centration (Tmax) in breast milk was calculated as 3.2 days. Milk to serum concentration ratios were: 0.0015, 0.00082 and 0.0014 for three patients [119].
3.4.10 Ustekinumab
In total 54 maternal pregnancies were investigated in 22 arti-cles. Outcomes regarding miscarriages were investigated for 27 of these pregnancies, in which three miscarriages were reported (11.1%). In one case of miscarriages the treatment dose of ustekinumab was higher than average due to refrac-tory Crohn’s disease [122, 124].
In 28 pregnancies investigated with regard to CMs, no cases were reported. Data on overall concomitant medication (including MTX exposure) were not available.
In one case with the last administered dose at 33 GW, concentration in cord blood at birth was measured (8 µg/ mL), which was higher than the drug concentration in the mother’s blood at the same point (4.3 µg/mL) [123].
Concentrations in breast milk were detectable in four cases from a total of six samples. Peak concentrations were
between 12 and 72 h after injection (range 0.72–1.57 μg/ mL). In three cases from four samples ustekinumab was still detectable 48 h after injection [80].
3.4.11 Vedolizumab
In total 147 maternal pregnancies were investigated in seven articles. Outcomes regarding miscarriages were investigated for 72 of these pregnancies, in which 19 miscarriages were reported (26.4%).
From 110 pregnancies investigated for major CMs, two cases were reported (1.8%). The descriptions of these CMs were as follows:
1. One congenital central nervous system anomaly caused by agenesis of the corpus callosum and left frontal pol-ymicrogyria. Estimated time of conception was 79 days after the vedolizumab infusion [132]
2. One case of congenital hypothyroidism [135].
One minor CM of hip dysplasia was also reported [131]. Data on overall concomitant medication were available for 34 cases. Use of one or more co-medications was reported for six of these patients (17.6%). Data on exposure to MTX were available for ten cases, of which none were exposed to MTX.
From a total of 28 investigated cases regarding stillbirth, one case was reported to the Organization of Teratology Information Services (OTIS) due to fetal growth restriction and decreased amniotic fluid volume-induced labor (26th week) [132].
Drug concentrations were measured in mothers’ serum and breast milk in the study by Lehat et al. [133]. No sta-tistically significant correlation was found in five patients with a serum concentration range of 4200–18,000 ng/mL and milk concentration range of 22–216 ng/mL (p = 0.11). Vedolizumab levels peaked at 3–4 days following infusion to a maximum of 480 ng/mL, and then slowly decreased [133]. Maternal and infants’ serum concentrations of vedoli-zumab were also measured in five patients [131]. The range of drug concentrations was 1.10–14.40 μg/mL in mothers and 1.00–8.70 μg/mL in infants at the time of delivery [131] (weight-adjusted doses were not reported).
One case of a preterm born child, who developed Kawa-saki disease with eosinophilia at 3 months, treated with cor-ticosteroids was reported [138]. In one study in 70 children exposed to vedolizumab during pregnancy there were no malignancies reported during the first year of life [134].
3.4.12 Other Biologics
The general conclusions of the articles, which could not be included in the above-mentioned subcategories, are dis-cussed in this section.
3.4.12.1 Secukinumab Only three case reports/series were found in the search between 1 January 2015 until 4 July 2019. In total five patients in these articles were reported, therefore this is not included in the results tables. Three of these cases reported spontaneous abortions and two resulted in live births. No information on CMs could
be found [60, 139, 140]. One retrospective research in a
Novartis global safety database was found on this subject; however, it was excluded from the final results as this was a research letter. Two congenital malformations from 54 total live births and 26 spontaneous abortions from 238 maternal pregnancies are reported. The type of CMs in maternal exposure was not specified with paternal expo-sure [141].
3.4.12.2 Belimumab There were two case reports on using belimumab during pregnancy, which were excluded as they were published as research letters. Therefore, this is not discussed in the results tables. One Ebstein anom-aly, one miscarriage, and one healthy birth were reported in a patient with systemic lupus erythematosus who was under belimumab treatment during three pregnancies. The mother was 41 years old at the time of the miscarriage [142]. The other case report was of a healthy birth after exposure to belimumab up to the 26th week of gestation. However, marked B-cell depletion and reduced T-cell sub-sets were reported in the baby at birth. B cells were in the normal range at 4 months of age. Rotavirus vaccina-tion 6 weeks after birth and diphtheria–tetanus–pertussis, haemophilus, and pneumococcus vaccinations at 3 and 5 months of age resulted in satisfactory responses [143].
3.4.12.3 TNFα Blocker (in General, Not Specified) Some of the publications discussed TNF-α blockers in general and did not mention separate data for each biologic. As the outcomes could not be related to one specific biologic with reported data, they were not discussed in the above subcategories [144–154]. In general, these studies have shown a higher chance of flare in patients who discon-tinue TNF-α blockers during pregnancy [144, 146]. Fur-thermore, a higher risk of pregnancy complications and severe acute respiratory infections in the first year of life in intrauterine-exposed infants were seen (specially in combination therapy with thiopurines and the chronic use of conventional steroids) [150].
Demyelinating disorders in children exposed to TNF-α blockers during pregnancy were investigated in a nested case–control study in 399 rheumatoid arthritis patients, which did not report any cases of demyelinating disorders in these children during the follow-up period [152].
3.4.12.4 Biologics (in General, Not Specified) In some of the included publications the type of biologic used was not specified for the outcomes. In general, these studies did not show any abnormal outcomes in children exposed to biologics during pregnancy/lactation [155–167]. 3.5 Risk of Bias Across Studies
The authors acknowledge that the risk of bias in total is high as the data are heterogenic and confounding factors could not be retrieved in all of the cases and from all of the stud-ies. Biologics used in different dosages and with different protocols for different indications were considered together in this article. However, it should be remembered that this will not affect the recognition of causality—if any—for CMs and miscarriages (aims of this study).
3.6 Additional Analysis
Additional data to the above-mentioned information have been acquired. As different publications had different pri-mary and secondary outcomes and because this additional information is scarce but still of importance, the authors see the necessity to summarize and present this data.
These further details for each biologic can be found in Tables 2, 3, and 4.
Comparison of the results regarding the rates of major CMs from this study with the rates in the systematic review of EULAR, are provided in ESM, Table 3.
4 Discussion
Available data extracted from the most recent published lit-erature shows that the rates of miscarriages and major CMs in investigated biologics do not differ drastically from those rates in the general population (estimated as 10–20% and 2–5.5%, respectively). In some cases the information on other outcomes (such as ADRs related to vaccination, pre-term births, etc.) was not available. Despite this fact and the heterogeneity of the data, no new safety concerns were iden-tified from a total of 143 investigated publications regarding the use of biologics during pregnancy.
Regarding the association of CMs, preterm birth, and birth weight with biologic use during pregnancy, a recent
meta-analysis by Tsao et al. also showed no increased odds ratios [11]. Nonetheless, it should be considered that the methods in the two studies are different. We have investi-gated a broader range of studies and have summed up data on miscarriages (co-primary outcome) and additional sec-ondary outcomes such as vaccination response and detect-able drug levels during different periods. We have also described the pattern of reported CMs. In our systematic review, each biologic was considered separately. This can be of additional value if one specific biologic is the matter of interest. The study of Tsao et al. showed that the underlying conditions are important factors to be considered as a poten-tial confounder for the pregnancy outcomes. In accordance with this conclusion, we provided detailed information on maternal disease baseline characteristics.
According to EMA guidelines, in order to exclude a ten- or twofold risk of congenital malformations for medicine use during pregnancy there is a need for at least 300 or 1000 prospectively collected sets of data on pregnancies, respec-tively. This information should be collected from exposed pregnancies to that particular pharmaceutical product during at least the first trimester [168, 169]. Based on summed up data in our study combined with the data from the EULAR study, it can be concluded that the use of adalimumab, cer-tolizumab pegol, and infliximab during pregnancy does not carry a twofold increased risk of combined major CMs for the offspring, compared to this risk in the general population (estimated as 2–5.5%) [170]. The rates of major CMs from this study were comparable with the rates in the systematic review of EULAR for most of the investigated biologics, with some minor differences [8]. The use of adalimumab, certolizumab pegol, infliximab, and etanercept during preg-nancy has been conditionally approved by the EMA recently, based on the results of their pregnancy registries conducted by pharmaceutical companies [4–7].
For several reasons the impact of medication on the inci-dence rate of miscarriages is difficult to determine. Often in prospective studies women are only included when they are pregnant and not in the pre-conception period. In these stud-ies early miscarriages are missed. In retrospective studstud-ies there is a chance of publication bias, as only women with an abnormal pregnancy are reported. Reliable data would only be available from prospective studies if women are included from the moment they actively try to become pregnant. Fur-thermore, confounding by indication (some diseases cause more miscarriages) and confounding by concomitant medi-cation (like MTX) can also affect the results. The results on miscarriages and malformations are comparable for adali-mumab, certolizumab, and etanercept, although the transpla-cental passage of adalimumab is extremely high.
In our study, only abatacept, tocilizumab, and ved-olizumab show slightly higher rates for miscarriage compared to the incidence rate of miscarriages in the
general population (estimated as 10–20%) [90]. It should be considered that the numbers of pregnancies investi-gated for miscarriages are limited for abatacept [153] and vedolizumab [72]. Due to limited numbers, it cannot be concluded that there is a causal relationship between a slightly higher rate of miscarriages and the use of abatacept or vedolizumab. Regarding tocilizumab, high percentages of miscarriages can be due to publication bias, as this percentage is higher in retrospective data compared to prospective data. For tocilizumab, the high rate of MTX use compared to other biologics can also explain the higher total rate of miscarriages. Compar-ing the results of miscarriages from this study with the systematic review of EULAR, the rates were comparable for most of the investigated biologics, with some minor differences as follows: rates of miscarriages for anakinra and rituximab were lower in our study versus the EULAR study (1/33 (3.1%) vs. 4/40 (10.0%) and 1/24 (4.2%) vs. 48/210 (22.9%), respectively). However, because of the small number of cases, these findings remain inconclu-sive [8].
From the secondary outcomes with acceptable reported sample sizes, the results were often as expected. Still there were some increased incidences detected, such as early membrane rupture, low birth weight, and pre-term birth rates with tocilizumab therapy during preg-nancy. Increased risk of all these three events have been described with the use of corticosteroids [171–173]. It should be noted that the rate of exposure to corticoster-oids in the reviewed publications for tocilizumab was high (Table 2).
Further, serious infections rates in children exposed to infliximab during pregnancy were higher than expected (212/786 (27%)). This highlights the need for continu-ing research evaluatcontinu-ing the safety of infliximab on vari-ous maternal infections and infections in offspring. Dif-ferent studies have shown that combination therapy with anti-TNF α and thiopurines during pregnancy is associ-ated with a higher rate of infections in offspring when compared to monotherapy with anti-TNF α [42, 136]. The overall rate of exposure to thiopurines for infliximab in our systematic review was 39.2%, higher than other biologics, which can explain the higher rates of serious infections in this group. Additionally, most of the reported infections were from the study by Truta et al., which reported acute respiratory infections, without differentiating the serious infections from non-serious infections. In this study, data acquisition was done retrospectively, which increases the chance of publication bias. Furthermore, in most of the pregnancies in this study infliximab was discontin-ued 90 days or less before delivery, therefore it is more likely that an immunoglobulin with a high affinity for the
neonatal Fc receptor (in this case infliximab) transfers through the placenta and reaches the fetus [111, 174].
From the available data on other secondary outcomes some subcategories may give the impression of an increased incidence compared to the normal population such as placental abnormality rate for infliximab and ved-olizumab (1/6 (16.7%) and 2/4 (50.0%), respectively), low birth-weight rate for anakinra (6/19 (31.6%)), anti-drug antibodies at birth (4/51 (7.8%)), and detectable drug lev-els at the 9th (7/46 (15.2%)) and 12th months of age (3/46 (6.5%)), in children exposed to infliximab during preg-nancy. However, conclusions should be drawn with caution regarding the above-mentioned increased incidences. 4.1 Limitations
The protocol of this study was recorded retrospectively in PROSPERO (after conducting the first search in the databases). Another limitation of this study is that the small sample sizes and small numbers of reports involved in some outcomes (especially secondary outcomes) make interpretations based on acquired results uncertain. Fur-thermore, type of disease, disease activity during preg-nancy, extent of systemic inflammation, and organ involve-ment, co-morbidities, and concomitant drug therapy could also have contributed to negative outcomes. In this study all types of rheumatologic, gastroenteric, and dermato-logic biodermato-logics were considered together as the types of biologics used in the management of these diseases over-lap. All the increased incidences should be further inves-tigated and confirmed in future studies, aiming to collect prospective data.
5 Conclusions
Based on the results of our study it is likely that adalimumab, certolizumab pegol, and etanercept conceivably can be pre-scribed safely during pregnancy, especially considering the negative effects of active disease on mothers, pregnancy out-comes, and the children. Regarding infliximab, high rates of infections in children have been detected, mainly from one study [111], and a more conservative approach, especially in combination therapy with thiopurines, is recommended. Discontinuation before the third trimester may decrease the chance of infections in offspring. Further, the risks of using abatacept, anakinra, canakinumab, golimumab, rituximab, tocilizumab, ustekinumab, and vedolizumab are not well known and available data are scarce in this regard. This study confirms the previous literature reviews carried out on use of biologics during pregnancy in autoimmune diseases.
Declarations
Funding This study was part of N. Ghalandari’s PhD project. The entire PhD project is funded by Dutch Medicines Evaluation Board (CBG-MEB).
Conflicts of interest Dr. R.J.E.M. Dolhain received an unrestricted
grant from UCB Pharma B.V. and the Dutch Arthritis Association. The other authors have no conflicts to declare.
Availability of data and material All data generated or analyzed during
this study are included in this published article (and its supplementary information files). All included articles are listed as references.
Code availability All articles were extracted from the following data-bases: Embase.com, Medline Ovid, Web of science, Cochrane CEN-TRAL, and Google scholar.
Author contributions NG: conceptualization, methodology, investiga-tion, resources, data curainvestiga-tion, writing the original draft, visualization. RJEMD: conceptualization, validation, writing—review and editing, supervision. JMWH: calidation, writing—review and editing, supervi-sion. EPvanP: validation, writing—review and editing, supervisupervi-sion. MK: resources, data curation, visualization. HJMJC: methodology, investigation, resources, data curation, validation, writing—review and editing, project administration.
Open Access This article is licensed under a Creative Commons
Attri-bution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Com-mons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regula-tion or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creat iveco mmons .org/licen ses/by-nc/4.0/.
References
1. Hoxha A, Calligaro A, Di Poi E, Peccatori S, Favaro M, Del Ross T, et al. Pregnancy and foetal outcomes following anti-tumor necrosis factor alpha therapy: a prospective multicentre study. Jt Bone Spine. 2017;84(2):169–73.
2. Marchioni RM, Lichtenstein GR. Tumor necrosis factor-alpha inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol. 2013;19(17):2591–602.
3. Tauscher AE, Fleischer AB, Phelps KC, Feldman SR. Psoriasis and pregnancy. JCMS. 2002;6(6):561–70.
4. EuropeanMedicinesAgency. Summary of Product Characteris-tics (SmPC) Etanercept (Enbrel) European Medicines Agency 2019; https ://www.ema.europ a.eu/docs/en_GB/docum ent_libra ry/EPAR_-_Produ ct_Infor matio n/human /00026 2/WC500 02736
1.pdf. Assessed July 2019.
5. EuropeanMedicinesAgency. Summary of Product Characteris-tics (SmPC) Infliximab (Remicade) European Medicines Agency 2019; https ://www.ema.europ a.eu/docs/en_GB/docum ent_libra
